NSPR earnings analysis
What we found in NSPR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text is materially negative because management disclosed substantial doubt about continuing as a going concern and the company faces a Nasdaq minimum-bid-price deficiency requiring remediation by January 13, 2027. The May 2026 voluntary recall of CGuard Prime adds product, regulatory, revenue, and litigation risk. The provided extract does not include Q2 2026 income-statement, balance-sheet, segment, or cash-flow tables, so current-period financial metrics and trends cannot be independently verified.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls deemed effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
- No material control changes
- The company reported no material changes to internal control over financial reporting during the quarter ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial doubt over going concern
- Management concluded that substantial doubt exists regarding the company’s ability to continue as a going concern. The concern is tied to recurring losses and negative operating cash flows for the quarter ended June 30, 2026, and could limit access to new financing on reasonable terms or at all.
- Nasdaq listing deficiency
- Nasdaq notified InspireMD on July 17, 2026 that it was below the $1.00 minimum bid-price requirement. The company has until January 13, 2027—180 calendar days from the notice—to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- CGuard Prime recall
- In May 2026, the company announced a voluntary U.S. recall of CGuard Prime after controlled launch testing showed that delivery-system technical success during carotid artery stenting procedures had not met performance expectations. The recall could result in inventory write-offs, refunds, lost revenue, regulatory action, litigation, and reputational damage.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; numeric outlook may be addressed in the earnings release or conference call.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 7, 2026
- InspireMD reported Q1 2026 revenues of $3.398 million, exceeding estimates by 17.85%. This represents a 122% year-over-year growth, while EPS improved to -$0.14 from -$0.18 in the prior year. Management signals ongoing…
- 10-K · March 18, 2026
- InspireMD (NSPR) is transitioning from a Europe/distributor business to a U.S. commercial stage company after FDA PMA approval of CGuard Prime on June 23, 2025 and a U.S. launch in July 2025. Clinical evidence…
- 10-Q · November 10, 2025
- Revenue rose 39.4% year-over-year to $2,523,000 in Q3 2025 while gross margin expanded to 34.2% from 22.9%, driven by the U.S. commercial launch of CGuard Prime. However, net loss widened to $12,708,000 (up $4,818,000…
- 10-Q · November 12, 2024
- InspireMD reported Q3 revenue of $1,810 (thousands), up from $1,556 in the prior-year quarter, but losses widened as operating expenses rose to $8,876 (thousands) and net loss was $(7,890) for the quarter. Cash +…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NSPR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever